PhRMA Launches National Campaign to Increase Diversity in Clinical Trials - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PhRMA Launches National Campaign to Increase Diversity in Clinical Trials
The I'm In campaign is designed to increase participation by diverse patient populations for clinical trials.


PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 4

The Pharmaceutical Research and Manufacturers of America (PhRMA) and the National Minority Quality Forum have developed a national campaign to help increase diversity in clinical trials.

The I’m In campaign will raise awareness about the importance of clinical research and increase participation by diverse patient populations to help researchers develop potential new medicines. Partnerships with patient advocacy organizations, provider groups, individual physicians, clinical trials sponsors, and researchers will help to drive campaign awareness and involvement.

According to FDA, African Americans represent 12% of the US population but only 5% of clinical trial participants and Hispanics make up 16% of the population but only 1% of clinical trial participants. Inclusion of individuals of varied races, ethnicities, ages, gender, and sexual orientation in clinical trials can help to prevent disparities in the evaluation of potential new medicines.

I’m In will support the National Minority Quality Forum’s Clinical Trial Engagement Network, a solution to help accelerate the inclusion of underrepresented populations in clinical trials. Authorized users will be able to identify potential clinical trial participants by using zip code level mapping of disease clusters and simultaneously identifying and connecting points of care and community resources that can assist with site selection and patient recruitment.

Source: Pharmaceutical Research and Manufacturers of America

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here